Tag: vaccination

NEW YORK, June 24, 2026 (GLOBE NEWSWIRE) -- The American Kennel Club (AKC^®), a not-for-profit organization that is the world’s largest registry of purebred and mixed-breed dogs, and a leading voice for canine welfare and responsible ownership, applauds the U.S. Senate Agriculture Committee’s base text for the 2026 Senate Agricultural Authorization Act, the “Farm Bill 2.0”. This measure accompanies and shares important positive priorities with the recently passed House Farm Bill (H.R. 7567, the Farm, Food, and National Security Act of 2026.) The bill reauthorizes key U.S. Department of Agriculture (USDA) programs through 2031 and serves as an important vehicle to address federal priorities in the federal Animal Welfare Act (AWA).

Langenfeld, Germany, June 03, 2026 (GLOBE NEWSWIRE) -- Booking Health today announced the release of findings examining international patient access to personalized dendritic cell therapy for glioblastoma in Germany. The findings, based on a documented Canadian patient case and supporting clinical research, highlight how cross-border treatment pathways may provide patients with aggressive brain tumors access to individualized immunotherapy options that are not widely available within all healthcare systems.

Saint Herblain (France), August 18, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that Health Canada has granted marketing authorization for its single-dose vaccine, IXCHIQ^®, for the prevention of disease caused by the chikungunya virus in individuals aged 12 years and older. This announcement adds to the adult marketing authorization already received in Canada¹ and complements the adolescent label extension received in Europe in April 2025².

OMAHA, Neb., Aug. 12, 2025 (GLOBE NEWSWIRE) -- TeleVox, the industry-leading provider of omnichannel patient relationship management, announced a new national group purchasing agreement with Premier, Inc., a leading healthcare improvement company serving over two-thirds of U.S. providers. Effective September 1, 2025, the agreement enables Premier members, at their discretion, to access pre-negotiated pricing and terms for TeleVox’s industry-leading solutions, including Digital Front Door, Appointment Management, Digital Care Programs, and Patient Marketing.

Saint Herblain (France), August 7, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the FDA has removed its recommended pause in the use of IXCHIQ^® in individuals 60 years of age and older and has approved updates to the Prescribing Information (PI) for IXCHIQ^®. IXCHIQ^® remains indicated in the United States for the prevention of disease caused by the Chikungunya Virus (CHIKV) in individuals 18 years of age and older who are at high risk of exposure to CHIKV.

Conference call and webcast scheduled for August 4, 2025, at 8:00 a.m. EDT (2:00 p.m. CEST)

WALTHAM, Mass., July 28, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the U.S. Food and Drug Administration (FDA) has approved EMPAVELI^® (pegcetacoplan) as the first treatment for C3 glomerulopathy (C3G) or primary immune complex membranoproliferative glomerulonephritis (IC-MPGN) in patients 12 years of age and older, to reduce proteinuria. C3G and primary IC-MPGN are rare kidney diseases, affecting 5,000 people in the United States.¹

NEW YORK and MAINZ, GERMANY, July 25, 2025 — Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) announced today that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended marketing authorization for the companies’ LP.8.1-adapted monovalent COVID-19 vaccine (COMIRNATY^® LP.8.1) for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 6 months of age and older. The adaptation is based on the recommendation from the EMA’s Emergency Task Force (ETF) to update COVID-19 vaccines to target the LP.8.1 variant for the 2025-2026 season. The ETF stated that “targeting LP.8.1 will help maintain the effectiveness of the vaccines as SARS-CoV-2 continues to evolve.”²

Efluelda^®, le vaccin haute dose de Sanofi contre la grippe, fait son retour en France pour la saison 2025-2026